MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 18, 2005; DOI: 10.1124/mol.104.010272


0026-895X/05/6706-2173-2184$20.00
Mol Pharmacol 67:2173-2184, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.010272v1
67/6/2173    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, D.
Right arrow Articles by Sadée, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, D.
Right arrow Articles by Sadée, W.

Opioid Receptor Homo- and Heterodimerization in Living Cells by Quantitative Bioluminescence Resonance Energy Transfer

Danxin Wang, Xiaochun Sun, Laura M. Bohn, and Wolfgang Sadée

Department of Pharmacology, School of Medicine and Public Health, The Ohio State University, Columbus, Ohio

Opioid receptors have been shown to dimerize or oligomerize among themselves and each other, affecting their functional properties. This study used bioluminescence resonance energy transfer (BRET) between the µ, {delta}, and {kappa} opioid receptors to study opioid receptor aggregation in transfected human embryonic kidney 293 cells. Titration of receptor levels indicated that all three opioid receptors have a similar affinity to form homo- or hetero-oligomers in combination with any other opioid receptor type. In contrast, none of the opioid receptors formed detectable oligomers with the muscarinic M2 receptor, indicating that interactions among opioid receptors are selective. The formation of opioid receptor dimers, rather than higher order oligomers, is supported by binding kinetics in competition experiments between labeled and unlabeled receptors. Opioid receptor dimerization occurred at physiological temperatures upon receptor biosynthesis, before trafficking to the plasma membrane. Moreover, using BRET, coimmunoprecipitation, receptor binding, and G protein coupling, we demonstrate for the first time functional µ opioid receptor-{kappa} opioid receptor heterodimerization. These combined results demonstrate that opioid receptors can undergo homo- and heterodimerization, a process with potential implications for opioid physiology and pharmacology.


Received December 13, 2004; accepted March 11, 2005

Address correspondence to: Dr. Wolfgang Sadée, Department of Pharmacology, School of Medicine and Public Health, The Ohio State University, Columbus, OH 43210. E-mail: sadee.1{at}osu.edu




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Ravindranathan, G. Joslyn, M. Robertson, M. A. Schuckit, J. L. Whistler, and R. L. White
Functional characterization of human variants of the mu-opioid receptor gene
PNAS, June 30, 2009; 106(26): 10811 - 10816.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
R. M. van Rijn and J. L. Whistler
The Only Way Is Up: Preventing Opioid Tolerance by Promoting Cell Surface Expression of MOR-DOR Heterodimers?
Mol. Interv., December 1, 2008; 8(6): 277 - 280.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
R. Rozenfeld and L. A. Devi
Receptor heterodimerization leads to a switch in signaling: {beta}-arrestin2-mediated ERK activation by {micro}-{delta} opioid receptor heterodimers
FASEB J, August 1, 2007; 21(10): 2455 - 2465.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Wang, X. Sun, and W. Sadee
Different Effects of Opioid Antagonists on {micro}-, {delta}-, and {kappa}-Opioid Receptors with and without Agonist Pretreatment
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 544 - 552.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
J.-P. Pin, R. Neubig, M. Bouvier, L. Devi, M. Filizola, J. A. Javitch, M. J. Lohse, G. Milligan, K. Palczewski, M. Parmentier, et al.
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers
Pharmacol. Rev., March 1, 2007; 59(1): 5 - 13.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. U. Gehret, A. Bajaj, F. Naider, and M. E. Dumont
Oligomerization of the Yeast {alpha}-Factor Receptor: IMPLICATIONS FOR DOMINANT NEGATIVE EFFECTS OF MUTANT RECEPTORS
J. Biol. Chem., July 28, 2006; 281(30): 20698 - 20714.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. C. Goin and N. M. Nathanson
Quantitative Analysis of Muscarinic Acetylcholine Receptor Homo- and Heterodimerization in Live Cells: REGULATION OF RECEPTOR DOWN-REGULATION BY HETERODIMERIZATION
J. Biol. Chem., March 3, 2006; 281(9): 5416 - 5425.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Zhang, D. Wang, A. D. Johnson, A. C. Papp, and W. Sadee
Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G
J. Biol. Chem., September 23, 2005; 280(38): 32618 - 32624.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Wilson, G. Wilkinson, and G. Milligan
The CXCR1 and CXCR2 Receptors Form Constitutive Homo- and Heterodimers Selectively and with Equal Apparent Affinities
J. Biol. Chem., August 5, 2005; 280(31): 28663 - 28674.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. S.-H. Park and K. Palczewski
Diversifying the repertoire of G protein-coupled receptors through oligomerization
PNAS, June 21, 2005; 102(25): 8793 - 8794.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics